145 related articles for article (PubMed ID: 17700528)
1. Aggressive breast cancer cells are dependent on activated Abl kinases for proliferation, anchorage-independent growth and survival.
Srinivasan D; Sims JT; Plattner R
Oncogene; 2008 Feb; 27(8):1095-105. PubMed ID: 17700528
[TBL] [Abstract][Full Text] [Related]
2. Activation of Abl tyrosine kinases promotes invasion of aggressive breast cancer cells.
Srinivasan D; Plattner R
Cancer Res; 2006 Jun; 66(11):5648-55. PubMed ID: 16740702
[TBL] [Abstract][Full Text] [Related]
3. Activated c-Abl tyrosine kinase in malignant solid tumors.
Lin J; Arlinghaus R
Oncogene; 2008 Jul; 27(32):4385-91. PubMed ID: 18391983
[TBL] [Abstract][Full Text] [Related]
4. A Src/Abl kinase inhibitor, SKI-606, blocks breast cancer invasion, growth, and metastasis in vitro and in vivo.
Jallal H; Valentino ML; Chen G; Boschelli F; Ali S; Rabbani SA
Cancer Res; 2007 Feb; 67(4):1580-8. PubMed ID: 17308097
[TBL] [Abstract][Full Text] [Related]
5. Differential insulin-like growth factor I receptor signaling and function in estrogen receptor (ER)-positive MCF-7 and ER-negative MDA-MB-231 breast cancer cells.
Bartucci M; Morelli C; Mauro L; Andò S; Surmacz E
Cancer Res; 2001 Sep; 61(18):6747-54. PubMed ID: 11559546
[TBL] [Abstract][Full Text] [Related]
6. Protein kinase D1 stimulates proliferation and enhances tumorigenesis of MCF-7 human breast cancer cells through a MEK/ERK-dependent signaling pathway.
Karam M; Legay C; Auclair C; Ricort JM
Exp Cell Res; 2012 Mar; 318(5):558-69. PubMed ID: 22245102
[TBL] [Abstract][Full Text] [Related]
7. Selective pyrrolo-pyrimidine inhibitors reveal a necessary role for Src family kinases in Bcr-Abl signal transduction and oncogenesis.
Wilson MB; Schreiner SJ; Choi HJ; Kamens J; Smithgall TE
Oncogene; 2002 Nov; 21(53):8075-88. PubMed ID: 12444544
[TBL] [Abstract][Full Text] [Related]
8. Upregulation and activation of PKC alpha by ErbB2 through Src promotes breast cancer cell invasion that can be blocked by combined treatment with PKC alpha and Src inhibitors.
Tan M; Li P; Sun M; Yin G; Yu D
Oncogene; 2006 Jun; 25(23):3286-95. PubMed ID: 16407820
[TBL] [Abstract][Full Text] [Related]
9. Arg/Abl2 promotes invasion and attenuates proliferation of breast cancer in vivo.
Gil-Henn H; Patsialou A; Wang Y; Warren MS; Condeelis JS; Koleske AJ
Oncogene; 2013 May; 32(21):2622-30. PubMed ID: 22777352
[TBL] [Abstract][Full Text] [Related]
10. Dasatinib, an orally active small molecule inhibitor of both the src and abl kinases, selectively inhibits growth of basal-type/"triple-negative" breast cancer cell lines growing in vitro.
Finn RS; Dering J; Ginther C; Wilson CA; Glaspy P; Tchekmedyian N; Slamon DJ
Breast Cancer Res Treat; 2007 Nov; 105(3):319-26. PubMed ID: 17268817
[TBL] [Abstract][Full Text] [Related]
11. RIN1 is an ABL tyrosine kinase activator and a regulator of epithelial-cell adhesion and migration.
Hu H; Bliss JM; Wang Y; Colicelli J
Curr Biol; 2005 May; 15(9):815-23. PubMed ID: 15886098
[TBL] [Abstract][Full Text] [Related]
12. Tyrosine phosphorylation and activation of focal adhesion kinase (p125FAK) by BCR-ABL oncoprotein.
Gotoh A; Miyazawa K; Ohyashiki K; Tauchi T; Boswell HS; Broxmeyer HE; Toyama K
Exp Hematol; 1995 Oct; 23(11):1153-9. PubMed ID: 7556524
[TBL] [Abstract][Full Text] [Related]
13. The GAB2 signaling scaffold promotes anchorage independence and drives a transcriptional response associated with metastatic progression of breast cancer.
Mira A; Isella C; Renzulli T; Cantarella D; Martelli ML; Medico E
Oncogene; 2009 Dec; 28(50):4444-55. PubMed ID: 19838208
[TBL] [Abstract][Full Text] [Related]
14. c-Abl and Arg are activated in human primary melanomas, promote melanoma cell invasion via distinct pathways, and drive metastatic progression.
Ganguly SS; Fiore LS; Sims JT; Friend JW; Srinivasan D; Thacker MA; Cibull ML; Wang C; Novak M; Kaetzel DM; Plattner R
Oncogene; 2012 Apr; 31(14):1804-16. PubMed ID: 21892207
[TBL] [Abstract][Full Text] [Related]
15. SKI-606, a 4-anilino-3-quinolinecarbonitrile dual inhibitor of Src and Abl kinases, is a potent antiproliferative agent against chronic myelogenous leukemia cells in culture and causes regression of K562 xenografts in nude mice.
Golas JM; Arndt K; Etienne C; Lucas J; Nardin D; Gibbons J; Frost P; Ye F; Boschelli DH; Boschelli F
Cancer Res; 2003 Jan; 63(2):375-81. PubMed ID: 12543790
[TBL] [Abstract][Full Text] [Related]
16. Focal adhesion kinase-related proline-rich tyrosine kinase 2 and focal adhesion kinase are co-overexpressed in early-stage and invasive ErbB-2-positive breast cancer and cooperate for breast cancer cell tumorigenesis and invasiveness.
Behmoaram E; Bijian K; Jie S; Xu Y; Darnel A; Bismar TA; Alaoui-Jamali MA
Am J Pathol; 2008 Nov; 173(5):1540-50. PubMed ID: 18832579
[TBL] [Abstract][Full Text] [Related]
17. Novel signaling molecules implicated in tumor-associated fatty acid synthase-dependent breast cancer cell proliferation and survival: Role of exogenous dietary fatty acids, p53-p21WAF1/CIP1, ERK1/2 MAPK, p27KIP1, BRCA1, and NF-kappaB.
Menendez JA; Mehmi I; Atlas E; Colomer R; Lupu R
Int J Oncol; 2004 Mar; 24(3):591-608. PubMed ID: 14767544
[TBL] [Abstract][Full Text] [Related]
18. PH006, a novel and selective Src kinase inhibitor, suppresses human breast cancer growth and metastasis in vitro and in vivo.
Ma JG; Huang H; Chen SM; Chen Y; Xin XL; Lin LP; Ding J; Liu H; Meng LH
Breast Cancer Res Treat; 2011 Nov; 130(1):85-96. PubMed ID: 21181437
[TBL] [Abstract][Full Text] [Related]
19. Compensatory PI3-kinase/Akt/mTor activation regulates imatinib resistance development.
Burchert A; Wang Y; Cai D; von Bubnoff N; Paschka P; Müller-Brüsselbach S; Ottmann OG; Duyster J; Hochhaus A; Neubauer A
Leukemia; 2005 Oct; 19(10):1774-82. PubMed ID: 16136169
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of c-ABL sensitizes breast cancer cells to the dual ErbB receptor tyrosine kinase inhibitor lapatinib (GW572016).
Lo YH; Ho PC; Zhao H; Wang SC
Anticancer Res; 2011 Mar; 31(3):789-95. PubMed ID: 21498698
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
